Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 262-272

  Martin, Tracey Amanda ^a   Jiang, Wen Guo ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Prognosis; Stem cell marker

Indexed keywords

ALPHA2 INTEGRIN; ALPHA6 INTEGRIN; BETA1 INTEGRIN; CD133 ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; CELL MARKER; HERMES ANTIGEN; PROSTATE STEM CELL ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BLOOD VESSEL; BONE METASTASIS; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER STEM CELL; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RNA EXTRACTION;

ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, NEOPLASM; BONE NEOPLASMS; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; FEMALE; GLYCOPROTEINS; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA2; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PEPTIDES; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84891922408     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2813     Document Type: Article

References (22)

1. Donnenberg VS, Donnenberg AD, Zimmerlin L, Landreneau RJ, Bhargava R, Wetzel RA, Basse P and Brufsky AM: Localization of CD44 and CD90-positive cells to the invasive front of breast tumors. Cytometry B Clin Cytom 78: 287-301, 2010.
2. Ginestier C, Korkaya H, Dontu G, Birnbaum D, Wicha MS and Charafe-Jauffret EI: The cancer stem cell: the breast cancer driver. Med Sci 23: 1133-1139, 2007 (In French).
3. + cells with cancer stem cell characteristics. Breast Cancer Res 10: R10, 2008.
4. Xiao Y, Ye Y, Yearsley K, Jones S and Barsky SH: The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol 173: 561-574, 2008.
5. Park SY, Lee HE, Li H, Shipitsin M, Gelman R and Polyak K: Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16: 876-887, 2010.
6. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, Hite KM, Alley M, Hollingshead M, Shoemaker RH and Niederhuber JE: Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 28: 649-660, 2010.
7. Paget S: The distribution of secondary growths of the breast. Lancet 1: 571-573, 1889.
8. Lin EH, Jiang Y, Deng Y, Lapsiwala R, Lin T and Blau CA: Cancer stem cells, endothelial progenitors, and mesenchymal stem cells: 'seed and soil' theory revisited. Gastrointest Cancer Res 2: 169-174, 2008.
9. Martin TA, Watkins G, Mansel RE and Jiang WG: Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur J Cancer 40: 2717-2725, 2004.
10. Martin TA, Pereira G, Watkins G, Mansel RE and Jiang WG: N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo, and is associated with clinical outcome in patients with breast cancer. Clin Exp Metastasis 25: 97-108, 2008.
11. Rahman M, Deleyrolle L, Vedam-Mai V, Azari H, Abd-El-Barr M and Reynolds BA: The cancer stem cell hypothesis: failures and pitfalls. Neurosurgery 68: 531-545, 2011.
12. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ and Peterse JL: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216: 141-150, 2008.
13. - phenotype. BMC Cancer 10: 411, 2010.
14. Cipak A, Mrakovcic L, Ciz M, Lojek A, Mihaylova B, Goshev I, Jaganjac M, Cindric M, Sitic S, Margaritoni M, Waeg G, Balic M and Zarkovic N: Growth suppression of human breast carcinoma stem cells by lipid peroxidation product 4-hydroxy-2-nonenal and hydroxyl radical-modified collagen. Acta Biochim Pol 57: 165-171, 2010.
15. neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun 397: 27-33, 2010.
16. Zhou L, Jiang Y, Yan T, Di G, Shen Z, Shao Z and Lu J: The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Res Treat 122: 795-801, 2010.
17. Fillmore C and Kuperwasser C: Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res 9: 303, 2007.
18. - phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Med Oncol 28: 745-752, 2011.
19. + phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat 133: 979-995, 2012.
20. Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringnér M, Vallon-Christersson J, Jönsson G, Holm K, Lövgren K, Fernö M, Grabau D, Borg A and Hegardt C: CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11: 418, 2011.
21. Guler G, Balci S, Costinean S, Ussakli CH, Irkkan C, Suren D, Sari E, Altundag K, Ozisik Y, Jones S, Bacher J, Shapiro CL and Huebner K: Stem cell-related markers in primary breast cancers and associated metastatic lesions. Mod Pathol 25: 949-955, 2012.
22. Akhtari M, Mansuri J, Newman KA, Guise TM and Seth P: Biology of breast cancer bone metastasis. Cancer Biol Ther 7: 3-9, 2008.